Recently, Momed Biotech has utilized its MechGen drug discovery platform to precisely identify novel neuroprotective pathway targets from massive datasets and lock in a lead drug molecule for Parkinson’s disease treatment. The molecule demonstrated promising results in preclinical studies, showing potential to rapidly advance into Phase II clinical trials for neurodegenerative indications—highlighting the formidable advantages of AI-aided drug discovery.

Recently, Professor Arieh Warshel, shareholder and Chief Scientist of Momed Biotech, was elected Honorary Chairman of the National Academy of Artificial Intelligence (NAAI).